Showing all 8 results

  • Glibenclamide, Metformin & Pioglitazone Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute chemical stability of the three highly reactive APIs.

    Active IngredientStrengthPrimary Clinical Function
    Glibenclamide USP/Ph.Eur.5 mgThe Secretagogue (Micro-Dose): Triggers rapid, potent insulin release from the pancreas to control acute post-prandial (after-meal) glucose spikes.
    Pioglitazone (as Hydrochloride) USP/Ph.Eur.15 mgThe Sensitizer (Micro-Dose): Reverses deep cellular insulin resistance in skeletal muscle and adipose tissue.
    Metformin Hydrochloride USP/Ph.Eur.500 mg (IR or ER)The Hepatic Anchor (Macro-Dose): Provides baseline suppression of liver glucose production. Frequently formulated in a sustained-release matrix to minimize severe GI side effects.
    ExcipientsMicrocrystalline Cellulose / Croscarmellose Sodium / Hypromellose / Magnesium Stearate / Premium Opadry FilmDiluent / Superdisintegrant / Binder (ER Polymer) / Lubricant (Engineered utilizing elite multi-stage geometric dilution to guarantee that the lethal 5mg micro-dose of Glibenclamide is flawlessly and evenly distributed throughout the massive 500mg Metformin matrix)

    *Pack Sizes: 10×10 Alu-Alu Blisters (Optimized specifically for strict, chronic diabetic dispensing regimens).

  • Hydrocortisone Oromucosal Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, Mucoadhesive Pellet/Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the highly hygroscopic polymers do not prematurely swell from atmospheric humidity.

    Active IngredientStrengthPrimary Clinical Function
    Hydrocortisone (as Sodium Succinate or Acetate) USP/Ph.Eur.2.5 mgGlobal Oral Pathology Standard: The definitive micro-dose engineered specifically for localized mucosal absorption, maximizing ulcer healing while neutralizing systemic exposure.
    ExcipientsCarbomer / Hypromellose (HPMC) / Lactose Monohydrate / Polycarbophil / Magnesium StearateBio-Adhesive Polymers / Matrix Former / Diluent / Lubricant (Engineered utilizing elite hydrophilic polymers that instantly cross-link upon contact with saliva, converting the hard tablet into an immovable, slow-release mucosal patch)

    *Pack Sizes: 10×10 Alu-Alu Blisters or Tubes of 20 (Optimized specifically for the short-term, acute treatment of cyclical ulcer outbreaks).

  • Ivabradine Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute chemical stability of the highly hygroscopic hydrochloride salt.

    Active IngredientStrengthPrimary Clinical Function
    Ivabradine (as Hydrochloride) USP/Ph.Eur.5 mgInitiation / Titration Standard: Base therapeutic unit utilized twice daily for the safe initiation of therapy, allowing the cardiologist to monitor resting heart rate before upward titration.
    Ivabradine (as Hydrochloride) USP/Ph.Eur.7.5 mgGlobal Maintenance Standard: High-efficacy adult maintenance dose to strictly maintain the resting heart rate between 50 and 60 beats per minute.
    ExcipientsLactose Monohydrate / Maize Starch / Maltodextrin / Colloidal Silicon Dioxide / Magnesium Stearate / Premium Opadry FilmDiluent / Binder / Glidant / Lubricant / Film-Coating (Engineered specifically using precise geometric dilution to ensure the micro-dose API is flawlessly distributed, preventing accidental bradycardia from “hot spots” in a poorly blended generic tablet)

    *Pack Sizes: 10×10 Blisters or Bottles of 56 (Optimized specifically for strict 28-day chronic cardiology dispensing regimens).

  • Lansoprazole Dispersible Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, MUPS-Based Dispersible Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute chemical survival of the delicate, moisture-sensitive micro-pellets.

    Active IngredientStrengthPrimary Clinical Function
    Lansoprazole (as Enteric-Coated Micro-Pellets) USP/Ph.Eur.15 mgMaintenance & Pediatric Standard: Base therapeutic unit for healing maintenance, pediatric GERD, and preventing NSAID-induced gastric ulcers.
    Lansoprazole (as Enteric-Coated Micro-Pellets) USP/Ph.Eur.30 mgAcute Healing Standard: High-efficacy adult dosing for the rapid healing of erosive esophagitis, active duodenal ulcers, and H. pylori eradication protocols.
    ExcipientsMethacrylic Acid Copolymer (Enteric Coat) / Crospovidone / Microcrystalline Cellulose / Mannitol / Sucralose / Strawberry FlavorAcid-Resistant Shield / Superdisintegrant / Diluent / Sweetener (Engineered specifically to create a highly palatable, rapid-burst suspension that masks the bitter API, ensuring high pediatric compliance and smooth NG tube transit)

    *Pack Sizes: 10×10 Alu-Alu Blisters (Optimized specifically for strict, highly monitored hospital and outpatient dispensing regimens).

  • Ledipasvir & Sofosbuvir Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, Dual-Active FDC Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles with specialized desiccants to ensure the absolute chemical survival of the complex antiviral APIs.

    Active IngredientStrengthPrimary Clinical Function
    Ledipasvir USP/Ph.Eur.90 mgThe NS5A Anchor: Potent inhibitor of viral assembly and secretion; highly effective against specific HCV genotypes.
    Sofosbuvir USP/Ph.Eur.400 mgThe NS5B Backbone: The globally recognized foundational DAA that forces viral RNA chain termination across multiple genotypes.
    ExcipientsCopovidone / Lactose Monohydrate / Microcrystalline Cellulose / Croscarmellose Sodium / Magnesium Stearate / Premium Opadry FilmBinder / Diluent / Superdisintegrant / Lubricant / Film-Coating (Engineered specifically to solve the massive solubility differences between the highly soluble Sofosbuvir and the poorly soluble Ledipasvir, guaranteeing synchronized gastric release and peak systemic absorption)

    *Pack Sizes: Bottles of 28 (Optimized specifically for the strict 4-week dispensing intervals required for 8, 12, or 24-week curative regimens).

  • Ledipasvir Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, Solid-Dispersion Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute chemical survival of the complex antiviral API.

    Active IngredientStrengthPrimary Clinical Function
    Ledipasvir USP/Ph.Eur.90 mgGlobal Hepatology Standard: The definitive daily dose required to maintain constant, paralyzing pressure on the NS5A viral protein across the entire 12-to-24 week curative cycle.
    ExcipientsCopovidone / Lactose Monohydrate / Microcrystalline Cellulose / Croscarmellose Sodium / Magnesium Stearate / Premium Opadry FilmSolubility Enhancer / Diluent / Superdisintegrant / Lubricant / Film-Coating (Engineered specifically utilizing Amorphous Solid Dispersion techniques with Copovidone to force the highly insoluble Ledipasvir to dissolve instantly in gastric fluid, guaranteeing maximum systemic bioavailability)

    *Pack Sizes: Bottles of 28 or 10×10 Blisters (Optimized specifically for strict 4-week dispensing intervals to match custom DAA combination regimens).

  • Linagliptin & Metformin Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Engineered, API-Segregated Bilayer Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute chemical stability of the highly hygroscopic combination.

    Active IngredientStrengthPrimary Clinical Function
    Linagliptin / Metformin HCl (IR)2.5 mg / 500 mg
    2.5 mg / 850 mg
    2.5 mg / 1000 mg
    Twice-Daily Standard: Immediate-release units designed to be taken twice a day with meals to provide rapid, meal-time incretin spikes alongside baseline hepatic suppression.
    Linagliptin / Metformin HCl (ER)5 mg / 1000 mg (ER)Once-Daily Premium Standard: High-efficacy Extended-Release therapy designed for ultimate patient compliance, delivering the full daily dose of Linagliptin while slowly trickling Metformin into the gut over 24 hours to prevent severe gastrointestinal side effects.
    ExcipientsHypromellose (HPMC) / Copovidone / Microcrystalline Cellulose / Magnesium Stearate / Premium Moisture-Barrier FilmER Polymer / Binder / Diluent / Lubricant (Engineered utilizing elite Bilayer Rotary Presses to physically separate the delicate 2.5mg/5mg Linagliptin dose from the massive, moisture-drawing Metformin layer, preventing cross-degradation)

    *Pack Sizes: 10×10 Alu-Alu Blisters or Bottles of 60 (Optimized specifically for strict, massive-volume chronic diabetic dispensing regimens).

  • Linagliptin Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, Moisture-Shielded Film-Coated Tablet, packed exclusively in highly secure Alu-Alu blister strips to ensure the absolute chemical stability of the delicate API.

    Active IngredientStrengthPrimary Clinical Function
    Linagliptin USP/Ph.Eur.5 mgThe Universal Standard: A single, high-efficacy maintenance dose that applies to all adult patients, regardless of age, hepatic function, or severe renal impairment.
    ExcipientsMannitol / Pregelatinized Starch / Copovidone / Magnesium Stearate / Premium Opadry FilmDiluent / Disintegrant / Binder / Moisture-Barrier Coating (Engineered specifically without highly hygroscopic components to prevent moisture absorption, ensuring rapid disintegration and maximum bioavailability of the 5mg payload)

    *Pack Sizes: 10×10 Alu-Alu Blisters (Optimized specifically for strict, massive-volume chronic diabetic dispensing regimens).